tildrakizumab

Phase 2

MERCK (MRK)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

MRKPDUFA$364.4B

Phase 2

FDA PDUFA Date tildrakizumab

tildrakizumab• Psoriasis

Oct 29Confirmed

Source

00%

Competitive Landscape

9 competitors in Psoriasis

Drug Information

Target Indication

Psoriasis

Clinical Trial

NCT01225731

Last updated: 1/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/17/2018

Ilumetri

Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Vericiguat tabletPhase 3

Heart Failure

Pegylated interferon alfa-2b (SCH 54031)Phase 3

Hepatitis C, Chronic

ElbasvirPhase 3

Hepatitis C

V260Phase 3

Rotavirus Gastroenteritis

MK-8591APhase 3

HIV-1 Infection

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts